Skip to main content

Table 2 Chronic Graft-versus-Host disease characteristics

From: Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation

Chronic GvHD characteristics at time of onset of cGvHD (n = 22)

All

Resolved cGvHD (n = 11), n (%)

Active cGvHD (n = 11), n (%)

p-value

Median days from transplantation to onset of cGvHD (IQR)

326 (208, 601)

350 (224, 595)

240 (151, 723)

1.0

Subcategories of cGvHD type at time of onset

Classic cGvHD

20 (90.9%)

10 (90.9%)

10 (90.9%)

1.0

Overlap cGvHD

2 (9.1%)

1 (9.1%)

1 (9.1%)

NIH severity of cGvHD at maximum severity

Mild

2 (9.1%)

1 (9.1%)

1 (9.1%)

.080

Moderate

11 (50.0%)

8 (72.7%)

3 (27.3%)

Severe

9 (40.9%)

2 (18.2%)

7 (63.6%)

Organ manifestations of cGvHD at maximum severity

Cutaneous

16 (72.7%)

8 (72.7%)

8 (72.7%)

1.0

Oral

13 (59.1%)

5 (45.5%)

8 (72.7%)

.387

Eye

9 (40.9%)

4 (36.4%)

5 (45.5%)

1.0

Lung

5 (22.7%)

3 (27.3%)

2 (18.2%)

1.0

Gastrointestinal

4 (18.2%)

3 (27.3%)

1 (9.1%)

.586

Liver

4 (18.2%)

4 (36.4%)

.090

Vaginal

4 (18.2%)

2 (18.2%)

2 (18.2%)

1.0

Fascia

2 (9.1%)

2 (18.2%)

.476

Joint

2 (9.1%)

1 (9.1%)

1 (9.1%)

1.0

Platelet count at cGvHD onset, thrombocytes/µl

Median (IQR)

224 (90, 325)

240 (90, 306)

175 (77, 387)

1.0

Platelet count at cGvHD onset

< 100/nL

6 (27.3%)

3 (27.3%)

3 (27.3%)

1.0

≥ 100/nL

16 (72.7%)

8 (72.7%)

8 (72.7%)

  1. Data presented are n (%) unless otherwise indicated
  2. cGvHD: chronic Graft-versus-Host disease; Resolved cGvHD: all signs of clinically activity of cGvHD have disappeared, past history of cGvHD, no immunosuppression; Active cGvHD: physician reported inflammatory manifestations of cGvHD; IQR: interquartile range; NIH: National Institutes of Health